220 related articles for article (PubMed ID: 24144417)
1. Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives.
Yasinzai M; Khan M; Nadhman A; Shahnaz G
Future Med Chem; 2013 Oct; 5(15):1877-88. PubMed ID: 24144417
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target identification and design of antileishmanial modulators.
Loiseau PM; Bories C
Curr Top Med Chem; 2006; 6(5):539-50. PubMed ID: 16719806
[TBL] [Abstract][Full Text] [Related]
3. Leishmaniasis: drugs in the clinic, resistance and new developments.
Ouellette M; Drummelsmith J; Papadopoulou B
Drug Resist Updat; 2004; 7(4-5):257-66. PubMed ID: 15533763
[TBL] [Abstract][Full Text] [Related]
4. Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Ortega V; Giorgio S; de Paula E
J Liposome Res; 2017 Sep; 27(3):234-248. PubMed ID: 28874072
[TBL] [Abstract][Full Text] [Related]
5. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
6. Leishmaniasis: efflux pumps and chemoresistance.
Leandro C; Campino L
Int J Antimicrob Agents; 2003 Sep; 22(3):352-7. PubMed ID: 13678842
[TBL] [Abstract][Full Text] [Related]
7. Promising nanotherapy in treating leishmaniasis.
de Souza A; Marins DSS; Mathias SL; Monteiro LM; Yukuyama MN; Scarim CB; Löbenberg R; Bou-Chacra NA
Int J Pharm; 2018 Aug; 547(1-2):421-431. PubMed ID: 29886097
[TBL] [Abstract][Full Text] [Related]
8. Mannosylated thiolated polyethylenimine nanoparticles for the enhanced efficacy of antimonial drug against Leishmaniasis.
Sarwar HS; Ashraf S; Akhtar S; Sohail MF; Hussain SZ; Rafay M; Yasinzai M; Hussain I; Shahnaz G
Nanomedicine (Lond); 2018 Jan; 13(1):25-41. PubMed ID: 29173059
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase 1B as a target against leishmaniasis.
D'Annessa I; Castelli S; Desideri A
Mini Rev Med Chem; 2015; 15(3):203-10. PubMed ID: 25769969
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Nanosystems and Strategies for Managing Leishmaniasis.
Vaghela R; Kulkarni PK; Osmani RAM; Bhosale RR; Naga Sravan Kumar Varma V
Curr Drug Targets; 2017; 18(14):1598-1621. PubMed ID: 27033193
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial peptides for leishmaniasis.
Cobb SL; Denny PW
Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
[TBL] [Abstract][Full Text] [Related]
12. Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis.
Singh K; Garg G; Ali V
Curr Drug Metab; 2016; 17(9):897-919. PubMed ID: 27549807
[TBL] [Abstract][Full Text] [Related]
13. New delivery strategies for the old pentavalent antimonial drugs.
Frézard F; Demicheli C
Expert Opin Drug Deliv; 2010 Dec; 7(12):1343-58. PubMed ID: 21029028
[TBL] [Abstract][Full Text] [Related]
14. Innovative Solutions for the Control of Leishmaniases: Nanoscale Drug Delivery Systems.
Wagner V; Minguez-Menendez A; Pena J; Fernández-Prada C
Curr Pharm Des; 2019; 25(14):1582-1592. PubMed ID: 31223081
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.
Jamshaid H; Din FU; Khan GM
J Nanobiotechnology; 2021 Apr; 19(1):106. PubMed ID: 33858436
[TBL] [Abstract][Full Text] [Related]
16. Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis.
Loiseau PM; Pomel S; Croft SL
Molecules; 2020 Sep; 25(18):. PubMed ID: 32916994
[TBL] [Abstract][Full Text] [Related]
17. Nanotechnological Strategies for Treatment of Leishmaniasis--A Review.
de Almeida L; Terumi Fujimura A; Del Cistia ML; Fonseca-Santos B; Braga Imamura K; Michels PAM; Chorilli M; Graminha MAS
J Biomed Nanotechnol; 2017 Feb; 13(2):117-33. PubMed ID: 29376626
[TBL] [Abstract][Full Text] [Related]
18. Use of liposomal nanoformulations in antileishmania therapy: challenges and perspectives.
Téllez J; Echeverry MC; Romero I; Guatibonza A; Santos Ramos G; Borges De Oliveira AC; Frézard F; Demicheli C
J Liposome Res; 2021 Jun; 31(2):169-176. PubMed ID: 32228210
[TBL] [Abstract][Full Text] [Related]
19. Leishmaniasis: current treatment and prospects for new drugs and vaccines.
Kedzierski L; Sakthianandeswaren A; Curtis JM; Andrews PC; Junk PC; Kedzierska K
Curr Med Chem; 2009; 16(5):599-614. PubMed ID: 19199925
[TBL] [Abstract][Full Text] [Related]
20. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
Singh N; Chatterjee M; Sundar S
Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
